267 related articles for article (PubMed ID: 12743326)
1. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
2. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
Tarumoto T; Nagai T; Ohmine K; Miyoshi T; Nakamura M; Kondo T; Mitsugi K; Nakano S; Muroi K; Komatsu N; Ozawa K
Exp Hematol; 2004 Apr; 32(4):375-81. PubMed ID: 15050748
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
Rosenhahn J; Weise A; Michel S; Hennig K; Hartmann I; Schiefner J; Schubert K; Liehr T; von Eggeling F; Loncarevic IF
Int J Oncol; 2007 Jul; 31(1):121-8. PubMed ID: 17549412
[TBL] [Abstract][Full Text] [Related]
8. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Tipping AJ; Deininger MW; Goldman JM; Melo JV
Exp Hematol; 2003 Nov; 31(11):1073-80. PubMed ID: 14585372
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
11. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
12. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Alessandro R; Fontana S; Giordano M; Corrado C; Colomba P; Flugy AM; Santoro A; Kohn EC; De Leo G
J Cell Physiol; 2008 Apr; 215(1):111-21. PubMed ID: 17924401
[TBL] [Abstract][Full Text] [Related]
13. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
[TBL] [Abstract][Full Text] [Related]
16. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
[TBL] [Abstract][Full Text] [Related]
17. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
19. Resistance to targeted therapy in chronic myelogenous leukemia.
Hochhaus A; Erben P; Ernst T; Mueller MC
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
[TBL] [Abstract][Full Text] [Related]
20. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
